OUR CLIENTS
We believe in flexible and proactive partnerships with our clients
PIKPOK
PikPok was founded in 1997 and is one of New Zealand's most successful videogame developers, working both independently and in partnership with some of the world’s biggest videogames brands. With a library of dozens of original games available in countries around the world through a variety of different platforms, trade mark protection has played a crucial role in maximising value in PikPok’s intellectual property rights.
​
Founder and managing director, Mario Wynands, says: "As a creator and publisher of original entertainment, our intellectual property is everything, and protecting that property is of paramount importance. Building out our compelling characters, worlds, and brands is a huge investment of time and capital, and knowing we have appropriate IP rights, protections, and professional support in place allows us to forge ahead confidently."
INHIBIT COATINGS
Inhibit Coatings develops world-leading antimicrobial technology that permanently binds silver nanoparticles to materials for long-lasting, non-leaching protection. Their materials are proven to kill up to 99.999% of pathogens, making the technology ideal for medical devices, coatings, and use in hygiene-critical environments. Unlike traditional antimicrobial systems that release biocides over time, Inhibit Coatings’ silver nanoparticles are integrated with polymer chains, providing consistent broad-spectrum efficacy against over 650 microorganisms.
Inhibit Coatings has worked with Catalyst Intellectual Property since its founding in 2016. Together, we have secured meaningful worldwide patent protection for their polymer technology and continue to work together to identify and protect new inventions effectively and efficiently.
​
Inhibit Coatings say:
​
"We enjoy a productive and trusted relationship with Catalyst. Their deep technical expertise and strategic approach make the patent process feel straightforward and stress-free. "
EVERYONE
Not everyone understands the value of selecting and registering a strong distinctive trade mark, but Everyone does. And they encourage their clients to do the same.
​
Everyone is a team of creative storytellers based in Wellington, Aotearoa, New Zealand who work with clients regionally, nationally and internationally to tell their story.
​
Backed with 30 years of brand building and story telling experience, Everyone focusses on expressing the story you want the world to see and hear. They create bold, strong and visually impactive trade marks after taking the time to understand a client’s world.
​
Everyone works with Catalyst IP to ensure the trade marks they are pitching to clients are available and meet registration criteria. We work collaboratively together to ensure we capture the magic of the story being told. Being involved early in the research and development process, means Catalyst IP can advise on how best to protect new developments and products, ensuring opportunities that could lead to a competitive advantage aren't missed.
“Catalyst are a well trusted partner and an integral part of our naming and IP process when developing new brand identities or changing existing ones. They help us formulate our shortlisted names to ensure what we present back to our clients is well informed, highlighting any opportunities or obstacles each name might have”.
RODD & GUNN
Established in 1987, Rodd & Gunn is one of New Zealand’s best known menswear brands. Starting with its first store in Queen Street, Auckland, Rodd & Gunn now have stores across Australia, the United States, the United Kingdom, Canada, Ireland, Denmark, Italy, Belgium, France, Singapore and Hong Kong. Expansion into numerous other countries has been made possible by Rodd & Gunn’s online store. A successful strategy of trade mark development, registration and defence has allowed Rodd & Gunn to boast a significant reputation in the industry, further strengthening the business. With diversification into the hospitality industry in 2016, the validity and weight of Rodd & Gunn’s trade mark portfolio is now more crucial than ever.
![RG_NZ_LOGO_PRIMARY_REVERSE[25].png](https://static.wixstatic.com/media/94efd9_144f6764d99f4597ba1f8ac44f89e968~mv2.png/v1/fill/w_500,h_171,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/94efd9_144f6764d99f4597ba1f8ac44f89e968~mv2.png)
GREYWACKE
WILD SAUVIGNON
Building a global brand takes time, patience and care; much like producing high-quality wines.
​
From the outset, Kevin and Kimberley Judd recognised that having a distinctive brand and unique wine styles would set them apart from competitors. Greywacke worked tirelessly to develop both.
​
The brand GREYWACKE originates from New Zealand’s most prolific bedrock. A sedimentary rock, greywacke can be found throughout Marlborough vineyards. Greywacke’s wines are primarily based on sauvignon blanc and pinot noir — the sauvignon being produced in two distinctly different styles, with its indigenous fermented WILD SAUVIGNON having its own trade mark.
​
Alongside winemaking, founder Kevin Judd developed a parallel career in photography, becoming equally renowned for his copyright protected images of grapes and vineyards. Kevin was honoured in 2025 as the recipient of Marlborough’s Living Cultural Treasure Award. Kevin’s distinctive vineyard photographs are a signature touch to each Greywacke wine label.
​
Intellectual property is woven throughout everything Greywacke does. Having a strong and memorable trade mark and visually appealing labels has established a clear association between Greywacke, wine quality and international reputation.
​
“Having a unique and memorable brand name is paramount to creating a successful wine business,” says Kevin Judd. “Keeping it unique to our company has been a vital and challenging facet of building Greywacke, especially with exports to over 50 countries. The Catalyst team have helped us navigate the global IP minefield, giving us sound advice at every new juncture.”
​
FRAMECAD
FRAMECAD is the world-leader of steel framing building innovation. Founded in 1987 by Mark Taylor, the business began with selling roofing products in New Zealand, and has grown to provide cold-formed steel construction goods and services in over 100 countries worldwide. FRAMECAD provides a world-class, end-to-end solution that simplifies, automates, and optimizes construction processes—from design, manufacturing, build and deliver, all the way to the jobsite.
​
Throughout all developments, FRAMECAD has recognised the value in its intellectual property and the importance of ensuring exclusive intellectual property rights are identified and protected. This includes protecting its trademarks to ensure the FRAMECAD brand is the gold standard for high-quality products and services in cold-formed steel construction in all its international markets.
PACIFIC EDGE
Pacific Edge Limited is one of New Zealand’s most successful biotechnology companies. It listed on the
New Zealand Stock Exchange (NZX) in 2002 and entered the NZX 50 Index ranked 38 in September 2020. Pacific Edge has a current market capitalisation of approximately NZ$850M. It has successfully developed and commercialised a suite of four molecular diagnostic products. This includes a commercial portfolio of Cxbladder® cancer diagnostic products involving a non-invasive urine test that utilises genotypic and phenotypic biomarkers to quickly and accurately detect or rule out bladder cancer in patients undergoing initial investigation or post-treatment surveillance of the disease.
Pacific Edge’s commercial products seek to address a number of important shortcomings in the clinical pathway for bladder cancer detection and management including the need for earlier detection, non-invasive testing, the ability to rule out non-cancer patients who present with symptoms, as well as offering significantly greater accuracy, repeatability and reliability.
Pacific Edge’s success has been recognised through several industry awards including The NZ Innovators Award 2013, NZBIO Biotech Company of the Year Award 2014, Medical Technology Association of
New Zealand Innovation Award 2016 and TIN Top 10 Hot Emerging Companies in 2016 and 2017.
Catalyst Intellectual Property works closely with Pacific Edge providing high-level IP strategy advice and managing an extensive portfolio of proprietary intellectual property rights including in excess of 300 patents and 40 registered trade marks across multiple jurisdictions.
CHITOGEL
Advanced sinus surgery techniques like functional endoscopic sinus surgery offer greater precision and less invasiveness, improving patient outcomes. Traditionally, recovery involved painful removal of temporary surgical packing. Wellington-based Chitogel Limited provides a gentler alternative with its dissolvable Chitogel® hydrogel, launched in 2019 in the U.S. and New Zealand. Applied after surgery, it prevents bleeding, supports healing, and dissolves with saline, avoiding trauma. The technology originated from a collaboration between researchers at the University of Otago, the University of Adelaide, and a Wellington surgeon. Chitogel has since refined the product for surgical use and continues to invest in innovation and clinical trials.
​
Catalyst Intellectual Property works with Chitogel to secure their intellectual property rights, and provide an IP perspective in product development, clinical trials, and commercial agreements. Chitogel Acting CEO, Andrew Park, says “Catalyst IP’s advice and their comprehensive international network of partners has been critical in cost-effectively and efficiently securing our international trademark and securing additional patent protection of our new developments. They continue to act as a key partner to Chitogel while we develop our pipeline technology further to capitalise on new clinical applications”.
INSITUGEN
InsituGen Limited, a promising new start-up incorporated in 2020, has developed proprietary assay technology to enable rapid and accurate detection of anabolic drugs including “designer” drugs that have not been previously characterised. The assays are highly sensitive and specific, quick and simple to use enabling biological samples such as plasma, serum and urine, supplement extracts, and other matrices such as feed to be tested.
The commercial potential is vast and includes routine trackside testing to determine sports doping in (e.g.) human, equine and canine athletes, as well as in the detection of various performance enhancing substances present in food supplements.
The technology is the brainchild of Professor Alison Heather of the University of Otago. Initially incubated by Otago Innovation Limited, the University’s technology transfer office, Catalyst Intellectual Property has been working with Professor Heather and Otago Innovation Limited since 2015. Catalyst Intellectual Property is very pleased to continue its involvement in supporting InsituGen Limited by providing strategy advice and services with respect to its proprietary technology rights, advising on infringement considerations relevant to its path to market, and in the procurement of registered trade marks to support existing testing services.
FERRIER RESEARCH INSTITUTE
The Ferrier Research Institute at Victoria University of Wellington conducts specialized carbohydrate chemistry research led by Professor Gary Evans, spanning drug discovery, cancer immunology, and renewable polymers. Their 30+ year collaboration with Albert Einstein College of Medicine, particularly with Professor Vern Schramm, began in 1994 and has generated significant scientific advancements. The teams specialize in designing compounds that mimic enzyme transition states to create potential therapeutic agents. Their work has produced drug candidates for T-cell cancers, psoriasis, and gout.
Catalyst Intellectual Property, working with Albert Einstein College of Medicine’s New York patent attorneys, has developed one of New Zealand's most valuable pharmaceutical patent portfolios, facilitating seven-figure licensing deals with pharmaceutical companies.
Professor Peter Tyler received the 2017 MacDiarmid Medal for his revolutionary drug design technology targeting enzymes in diseases including cancer and Alzheimer's.